Will the ResVax Vaccine Be Key Revenue Driver for Novavax? - Market Realist
Will the ResVax Vaccine Be Key Revenue Driver for Novavax? Market Realist
On February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM.
Comments
Post a Comment